LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines.
LifeMine Therapeutics has raised $175.0M in total funding. The most recent round was Series C. The last funding was announced in March 2022.
LifeMine Therapeutics's investors include ARCH Venture Partners, Foresite Capital, Merck, Fidelity, Google Ventures.
LifeMine Therapeutics is headquartered in Cambridge, United States.
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines.
LifeMine Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LifeMine Therapeutics — Funding & Investors." VCBacked, March 23, 2022, https://www.vcbacked.co/company/lifemine-therapeutics. Accessed September 29, 2026.
VCBacked. (2022). LifeMine Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/lifemine-therapeutics
{{cite web |title=LifeMine Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/lifemine-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated